Therapeutic Solutions International Spin-Off Campbell Neurosciences Explains Why Suicide is a Disease and How to Predict it in Newly Released Video

Therapeutic Solutions International Patents Modified StemVacs Dendritic Cell Immunotherapy to Suppress Parkinson’s Disease in Animal Model

Therapeutic Solutions International Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc.

Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage

Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC

Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

Therapeutic Solutions International Optimizes Targeting the “Achilles Heel” of Cancer Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC

Therapeutic Solutions International Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration

Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board

Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model

Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell

Therapeutic Solutions International Comes to Agreement with FDA on Clinical Trial Design for First Stem Cell Clinical Trial in Chronic Traumatic Encephalopathy (CTE) Patients

Therapeutic Solutions International Spin-Off Campbell Neurosciences Identifies Mechanism of Action for Umbilical Cord Blood Derived NarcoStem™ Drug Rehabilitation Product

Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Efficacy of Kaihani Score in Prediction of Gambling Addiction

Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies

Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels

Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V™ iPSC Derived Cancer Immunotherapeutic

Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™

Therapeutic Solutions International Reports Reduction of Tumor Blood Vessels in Mouse Melanoma Model Treated with StemVacs

Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention

Therapeutic Solutions International Approved on RangeMe to sell QuadraMune™ and NanoStilbene™ along with other supplements

Therapeutic Solutions International Approved by Amazon to sell its highly regarded immune supplement QuadraMune™ along with other brands.

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™

Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells

Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board

Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease

Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer

Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC

Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma

Therapeutic Solutions International Reports Enhancement of StemVacs Immune Stimulating Activity Using Neuromodulatory Compound Homotaurine

Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy

Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences

Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity

Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company

Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction

Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell

Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention

Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder

Therapeutic Solutions International Announces Clinical Trial Assessing “Kaihani Score” Proprietary Biomarker Based Assay for Quantifying Gambling Addiction

Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data

QuadraMune™ Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial

Therapeutic Solutions International Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene™ Nutraceutical Product

Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score™

JadiCell™ Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double Blind FDA Clinical Trial

Therapeutic Solutions International Identifies New Mechanism of Mesenchymal Stem Cell Treatment of Brain Injury

Therapeutic Solutions International Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene™

Therapeutic Solutions International Appoints Serena Robella as Director of Sales

Therapeutic Solutions International announced today appointment of J Christopher Mizer to the Advisory Board of its Campbell Neurosciences Division

Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury 

Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy

Therapeutic Solutions International Files Comprehensive Campbell Platform™ Patent for Stem Cell Immunotherapy of Schizophrenia

Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune™ and Minocycline

Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers

Therapeutic Solutions International Launches Campbell Neurosciences Division aimed at Biologically Identifying and Repairing Suicide-Prone Brains

Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain Protective Biological Pathways

Therapeutic Solutions International Reports Unexpected Findings of Synergy between QuadraMune™ and Diabetes Drug Metformin in Animal Models of COVID-19 Lung Damage

Therapeutic Solutions International Reports QuadraMune™ Inhibits Inflammation Induced Blood Clotting: Possible Implication for Ongoing Covid-19 Prevention Clinical Trial?

Therapeutic Solutions International Submits Publication on StemVacs™ Preclinical Data Supporting COVID-19 Indication

Therapeutic Solutions International Universal Donor Immunotherapy StemVacs™ Activates Antiviral Immune Cells While Protecting Lungs From “Cytokine Storm” 

Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19

Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune™ in Animal Studies

Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer

Therapeutic Solutions International Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune™

Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19

San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune™ Immune Boosting Data in Clinical Trial 

San Diego “Top Doctor” James Veltmeyer Collaborates With Therapeutic Solutions International in Cord Blood Based Immunotherapy for COVID-19 Damaged Lungs

Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune™

Therapeutic Solutions International Enters into Multi-Million Dollar Master Sales Agreement with Publicly Traded iBrands Corporation

Therapeutic Solutions International Reports Inhibition of Microglial Activation with NeuroStilbene

Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With WCTE, Inc. 

Therapeutic Solutions International Signs Letter of Intent to License Adult Stem Cell Therapy for Treatment of Chronic Traumatic Encephalopathy to WCTE, Inc., a Wes Chandler Company

Therapeutic Solutions International Enters Into Multi-million Dollar Master Sales Agreement With Tiva Bio

Therapeutics Solutions International Signs Agreement With Beijing Regenesis Biotechnology to License and Develop Patent for Anti-aging Use of Cord Blood Plasma and NanoStilbene

Therapeutic Solutions International Reports Augmentation of Rejuvenating Activity of Cord Blood Plasma by Pterostilbene

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patient

Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development

NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer

Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA

Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)

Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell for Treatment of Military and Sports Brain Injuries

Therapeutic Solutions International Continues to Refine NanoStilbene™ Formulation

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

NanoStilbene Enhances Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Therapeutic Solutions International Signs Agreement for Licensing JadiCell’s Universal Donor Adult Stem Cell Product for Chronic Traumatic Encephalopathy and Traumatic Brain Injury

Therapeutic Solutions International Expands Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation

Therapeutic Solutions International Files Patent on Clinical Data Demonstrating Reduction of Inflammatory Cytokines Using NanoStilbene™

Therapeutic Solutions International Collaborates with Internationally Renowned Neurologist and NFL Charger Hall of Famer to Develop New Intellectual Property for Treatment of Chronic Traumatic Encephalopathy

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients

Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Player

TSOI Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Deliver

Therapeutic Solutions International Recruits Internationally Recognized Cancer Immunotherapy Pioneer Dr. Francesco Marincola to Accelerate StemVacs and NanoStilbene Clinical Development

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for Rapid Access to Blood-Brain Barrier

Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board

Therapeutic Solutions International Announces Clinical Proof of Concept of Nanoparticle Pterostilbene Formulation: NanoStilbene™

Therapeutic Solutions International Releases “IsoStilbene” Injectable Formulation of Pterostilbene Under Granted Patent for Augmentation of Immunotherapy and Targeting of Cancer Stem Cells

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

Therapeutic Solutions International Expands Adoptive Immunotherapy Portfolio by Incorporation of “Universal Cancer Antigen” into StemVacs Dendritic Cell Platform

Therapeutic Solutions International Announces Licensing of Additional Technologies to Pan American Cancer Treatment Center

Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Newly Passed Right to Try Law

Therapeutic Solutions International Releases “DermalStilbene” a Topical Formulation of Pterostilbene

Therapeutic Solutions International, Inc., to Initiate Clinical Trial of Patented Cancer Immunotherapy Adjuvant NanoStilbene

Therapeutic Solutions International, Inc., Announces the Appointment of Nassir Azimi, MD, to Science Board

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment Centers

Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene

Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board

Therapeutic Solutions International, Inc. strengthens the TSOI Scientific Advisory Board with the Appointment of Pablo A. Guzman, MD 

Therapeutic Solutions International, Inc. files new patent for the Synergistic Inhibition of Glioma Using Pterostilbene

Therapeutic Solutions International Returns to Fully Reporting Status with SEC

For Older Press Releases Visit MarketWired